Elevated progesterone receptor membrane component 1/sigma-2 receptor levels in lung tumors and plasma from lung cancer patients

International Journal of Cancer

Volumn 131, Issue 2, 2012, Pages

  Mir, Shakeel U R ^a   Ahmed, Ikhlas S A ^a   Arnold, Susanne ^a   Craven, Rolf J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

biomarker; cell survival; cytochrome; lung cancer

Indexed keywords

AG 205; ANTINEOPLASTIC AGENT; CYTOKERATIN; HEME; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR MEMBRANE COMPONENT 1; SIGMA 2 OPIATE RECEPTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG SQUAMOUS CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; TUMOR DIFFERENTIATION; UPREGULATION; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL; RECEPTORS, PROGESTERONE; RECEPTORS, SIGMA; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL;

EID: 84861632585     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26432     Document Type: Article

References (48)

1. Jha P,. Avoidable global cancer deaths and total deaths from smoking. Nat Rev Cancer 2009; 9: 655-64.
2. Sequist LV, Lynch TJ,. EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annu Rev Med 2008; 59: 429-42.
3. Gazdar AF,. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009; 28 (Suppl 1): S24-31.
4. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
5. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004; 101: 13306-11.
6. Gerdes D, Wehling M, Leube B, Falkenstein E,. Cloning and tissue expression of two putative steroid membrane receptors. Biol Chem 1998; 379: 907-11.
7. Mifsud W, Bateman A,. Membrane-bound progesterone receptors contain a cytochrome b5-like ligand-binding domain. Genome Biol 2002; 3: RESEARCH0068.
8. Ahmed IS, Rohe HJ, Twist KE, Craven RJ,. Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity. J Biol Chem 2010; 285: 24775-82.
9. Crudden G, Chitti RE, Craven RJ,. Hpr6 (heme-1 domain protein) regulates the susceptibility of cancer cells to chemotherapeutic drugs. J Pharmacol Exp Ther 2006; 316: 448-55.
10. Nolte I, Jeckel D, Wieland FT, Sohn K,. Localization and topology of ratp28, a member of a novel family of putative steroid-binding proteins. Biochim Biophys Acta 2000; 1543: 123-30.
11. Peluso JJ, Romak J, Liu X,. Progesterone receptor membrane component-1 (PGRMC1) is the mediator of progesterone's antiapoptotic action in spontaneously immortalized granulosa cells as revealed by PGRMC1 small interfering ribonucleic acid treatment and functional analysis of PGRMC1 mutations. Endocrinology 2008; 149: 534-43.
12. Peluso JJ, Pappalardo A, Losel R, Wehling M,. Progesterone membrane receptor component 1 expression in the immature rat ovary and its role in mediating progesterone's antiapoptotic action. Endocrinology 2006; 147: 3133-40.
13. Peluso JJ, Liu X, Gawkowska A, Lodde V, Wu CA,. Progesterone inhibits apoptosis in part by PGRMC1-regulated gene expression. Mol Cell Endocrinol 2010; 320: 153-161.
14. Krebs CJ, Jarvis ED, Chan J, Lydon JP, Ogawa S, Pfaff DW,. A membrane-associated progesterone-binding protein, 25-Dx, is regulated by progesterone in brain regions involved in female reproductive behaviors. Proc Natl Acad Sci USA 2000; 97: 12816-21.
15. Szczesna-Skorupa E, Kemper B,. Progesterone receptor membrane component 1 (Pgrmc1) inhibits the activity of drug-metabolizing cytochromes P450 and binds to cytochrome P450 reductase. Mol Pharmacol 2010; 79: 340-350.
16. Hughes AL, Powell DW, Bard M, Eckstein J, Barbuch R, Link AJ, Espenshade PJ,. Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. Cell Metab 2007; 5: 143-9.
17. Mansouri MR, Schuster J, Badhai J, Stattin EL, Losel R, Wehling M, Carlsson B, Hovatta O, Karlstrom PO, Golovleva I, Toniolo D, Bione S, et al. Alterations in the expression, structure and function of progesterone receptor membrane component-1 (PGRMC1) in premature ovarian failure. Hum Mol Genet 2008; 17: 3776-83.
18. Min L, Strushkevich NV, Harnastai IN, Iwamoto H, Gilep AA, Takemori H, Usanov SA, Nonaka Y, Hori H, Vinson GP, Okamoto M,. Molecular identification of adrenal inner zone antigen as a heme-binding protein. FEBS J 2005; 272: 5832-43.
19. Xu J, Zeng C, Chu W, Pan F, Rothfuss JM, Zhang F, Tu Z, Zhou D, Zeng D, Vangveravong S, Johnston F, Spitzer D, et al. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun 2011; 2: 380.
20. Meyer C, Schmid R, Scriba PC, Wehling M,. Purification and partial sequencing of high-affinity progesterone-binding site(s) from porcine liver membranes. Eur J Biochem 1996; 239: 726-31.
21. Ahmed IS, Rohe HJ, Twist KE, Mattingly MN, Craven RJ,. Progesterone receptor membrane component 1 (Pgrmc1): a heme-1 domain protein that promotes tumorigenesis and is inhibited by a small molecule. J Pharmacol Exp Ther 2010; 333: 564-73.
22. Peluso JJ, Gawkowska A, Liu X, Shioda T, Pru JK,. Progesterone receptor membrane component-1 regulates the development and Cisplatin sensitivity of human ovarian tumors in athymic nude mice. Endocrinology 2009; 150: 4846-54.
23. Peluso JJ, Liu X, Saunders MM, Claffey KP, Phoenix K,. Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1. J Clin Endocrinol Metab 2008; 93: 1592-9.
24. Lodde V, Peluso JJ,. A novel role for progesterone and progesterone receptor membrane component 1 in regulating spindle microtubule stability during rat and human ovarian cell mitosis. Biol Reprod 2010; 84: 215-222.
25. Crudden G, Loesel R, Craven RJ,. Overexpression of the cytochrome p450 activator hpr6 (heme-1 domain protein/human progesterone receptor) in tumors. Tumour Biol 2005; 26: 142-6.
26. Neubauer H, Clare SE, Wozny W, Schwall GP, Poznanovic S, Stegmann W, Vogel U, Sotlar K, Wallwiener D, Kurek R, Fehm T, Cahill MA,. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. Breast Cancer Res 2008; 10: R85.
27. Irby RB, Malek RL, Bloom G, Tsai J, Letwin N, Frank BC, Verratti K, Yeatman TJ, Lee NH,. Iterative microarray and RNA interference-based interrogation of the SRC-induced invasive phenotype. Cancer Res 2005; 65: 1814-21.
28. Difilippantonio S, Chen Y, Pietas A, Schluns K, Pacyna-Gengelbach M, Deutschmann N, Padilla-Nash HM, Ried T, Petersen I,. Gene expression profiles in human non-small and small-cell lung cancers. Eur J Cancer 2003; 39: 1936-47.
29. Selmin O, Lucier GW, Clark GC, Tritscher AM, Vanden Heuvel JP, Gastel JA, Walker NJ, Sutter TR, Bell DA,. Isolation and characterization of a novel gene induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in rat liver. Carcinogenesis 1996; 17: 2609-15.
30. Nie AY, McMillian M, Parker JB, Leone A, Bryant S, Yieh L, Bittner A, Nelson J, Carmen A, Wan J, Lord PG,. Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol Carcinog 2006; 45: 914-33.
31. Yoshitani N, Satou K, Saito K, Suzuki S, Hatanaka H, Seki M, Shinozaki K, Hirota H, Yokoyama S,. A structure-based strategy for discovery of small ligands binding to functionally unknown proteins: combination of in silico screening and surface plasmon resonance measurements. Proteomics 2005; 5: 1472-80.
32. Mallory JC, Crudden G, Oliva A, Saunders C, Stromberg A, Craven RJ,. A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells. Mol Pharmacol 2005; 68: 1747-56.
33. Hand RA, Craven RJ,. Hpr6.6 protein mediates cell death from oxidative damage in MCF-7 human breast cancer cells. J Cell Biochem 2003; 90: 534-47.
34. Buschow SI, van Balkom BW, Aalberts M, Heck AJ, Wauben M, Stoorvogel W,. MHC class II-associated proteins in B-cell exosomes and potential functional implications for exosome biogenesis. Immunol Cell Biol 2010; 88: 851-6.
35. Baran J, Baj-Krzyworzeka M, Weglarczyk K, Szatanek R, Zembala M, Barbasz J, Czupryna A, Szczepanik A,. Circulating tumour-derived microvesicles in plasma of gastric cancer patients. Cancer Immunol Immunother 2010; 59: 841-50.
36. Kimura I, Yoshioka M, Konishi M, Miyake A, Itoh N,. Neudesin, a novel secreted protein with a unique primary structure and neurotrophic activity. J Neurosci Res 2005; 79: 287-94.
37. Kimura I, Nakayama Y, Yamauchi H, Konishi M, Miyake A, Mori M, Ohta M, Itoh N, Fujimoto M,. Neurotrophic activity of neudesin, a novel extracellular heme-binding protein, is dependent on the binding of heme to its cytochrome b5-like heme/steroid-binding domain. J Biol Chem 2008; 283: 4323-31.
38. Kimura I, Nakayama Y, Konishi M, Kobayashi T, Mori M, Ito M, Hirasawa A, Tsujimoto G, Ohta M, Itoh N, Fujimoto M,. Neuferricin, a novel extracellular heme-binding protein, promotes neurogenesis. J Neurochem 2010; 112: 1156-67.
39. Marek CJ, Wallace K, Durward E, Koruth M, Leel V, Leiper LJ, Wright MC,. Low affinity glucocorticoid binding site ligands as potential anti-fibrogenics. Comp Hepatol 2009; 8: 1.
40. Roy L, Laboissiere S, Abdou E, Thibault G, Hamel N, Taheri M, Boismenu D, Lanoix J, Kearney RE, Paiement J,. Proteomic analysis of the transitional endoplasmic reticulum in hepatocellular carcinoma: an organelle perspective on cancer. Biochim Biophys Acta 2010; 1804: 1869-81.
41. Shin BK, Wang H, Yim AM, Le Naour F, Brichory F, Jang JH, Zhao R, Puravs E, Tra J, Michael CW, Misek DE, Hanash SM,. Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J Biol Chem 2003; 278: 7607-16.
42. Labombarda F, Gonzalez SL, Deniselle MC, Vinson GP, Schumacher M, De Nicola AF, Guennoun R,. Effects of injury and progesterone treatment on progesterone receptor and progesterone binding protein 25-Dx expression in the rat spinal cord. J Neurochem 2003; 87: 902-13.
43. Cahill MA,. Progesterone receptor membrane component 1: an integrative review. J Steroid Biochem Mol Biol 2007; 105: 16-36.
44. Gribben JG,. Implications of the tumor microenvironment on survival and disease response in follicular lymphoma. Curr Opin Oncol 2010; 22: 424-30.
45. Ogino S, Galon J, Fuchs CS, Dranoff G,. Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011. Aug 9, epub ahead of print.
46. Ichinose Y, Yano T, Asoh H, Yokoyama H, Yoshino I, Katsuda Y,. Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer. An analysis in each pathologic stage. J Thorac Cardiovasc Surg 1995; 110: 601-5.
47. Takise A, Kodama T, Shimosato Y, Watanabe S, Suemasu K,. Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter. Cancer 1988; 61: 2083-8.
48. Kalluri R, Zeisberg M,. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.